Aminosidine (Paromomycin)

Brands of Aminosidine (Paromomycin) in Kenya

Considine®, Concepts
Daboral®, Cosmos Limited

Gabbrolal®, Pfizer

Gabbrosun, Zawadi Healthcare Ltd

Gaberol®, Oss-Chemie

Minodine®, Dawa Limited

Unibrol®, Universal Corporation Limited

Aminosidine (Paromomycin) in Kenya : Price, Cost, uses, use in pregnancy, and alcohol

Aminosidine (Paromomycin) Chemical Structure

Paromomycin ( Aminosidine) Mechanism (Mode ) of Action

Paromomycin is a protein synthesis inhibitor in nonresistant cells by binding to 16S ribosomal RNA. This broad-spectrum antibiotic soluble in water, is very similar in action to neomycin.

Aminosidine Sulphate (paromomycin) is an aminoglycoside antibiotic. Aminosidine has a broad spectrum of activity, including activity against protozoa especially Entamoeba histolytica, bacteria and cestodes. The drug is believed to act against both the trophozoite and encysted forms of Entamoeba. Aminosidine has an antibacterial spectrum similar to that of neomycin. Aminosidine is active against some gram-positive bacteria (e.g. some strains of Staphylococcus) and many gram-negative aerobic bacteria, but generally is inactive against Pseudomonas aeruginosa and anaerobic bacteria. Aminosidine also has some activity against Mycobacterium tuberculosis. Aminosidine has been shown to be active against certain cestodes (tapeworms) pathogenic to humans including Diphyllobothrium latum (fish tapeworm), Taenia saginata (beef tapeworm), and T.solium (pork tapeworm).
Aminosidine is poorly absorbed from the gastro-intestinal tract and most of the dose is eliminated unchanged in the faeces.


Paromomycin is used in the treatment of intestinal protozoal infections, including amoebiasis, cryptosporidiosis, and giardiasis. It has been used in the treatment of tapeworm infection. Also in the suppression of intestinal flora both pre-operatively and in the management of hepatic encephalopathy.
Prophylactic treatment of hepatic coma:
Adults: 2g daily for 6 days.
Children: 50mg/kg/day for 6 days
Paromomycin is administered orally, with or after meals, in 2-4 divided doses. The physician can also adjust the dosages and duration of treatment according to the severity and duration of the diseases.


Amoebiasis, Giardiasis (Lambliasis) and Balantidiasis:
Adults: 500mg twice a day for 5-7 days.
Children: 30mg/kg/day in two divided doses for 5-7 days.
Cryptosporidiosis: Adults: 500mg four times a day for 14 days.
Gastro-enteritis and enterocolitis due to mixed flora, salmonellosis and shigellosis:
Adults: 500mg twice a day for 5-7 days.
Children: 30mg/kg/day in two divided doses for 5-7 days.
Prophylactic sterilization in gastro-intestinal surgery:
Adults: 2g daily for 3 days.
Children: 50mg/kg/day for 3 days.


The use of Aminosidine may result in the overgrowth of nonsusceptible organisms, especially Candida, and patients should be carefully monitored for the development of new infections caused by nonsusceptible organisms. Secondary Staphylococcus enterocolitis may occur. Aminosidine should be administered with caution to patients with ulcerative intestinal lesions to avoid renal toxicity through inadvertent absorption of the drug. High doses or prolonged therapy with Aminosidine should be avoided. Since Aminosidine is only active against intestinal protozoa, the drug should not be used in the treatment of extraintestinal amoebiasis. Aminosidine is contraindicated in patients with intestinal obstruction and in patients with a known hypersensitivity to the drug.


Aminosidine has been reported to impair the absorption of other drugs including phenoxymethylpenicillin, digoxin and methotrexate; the efficacy of oral contraceptives might be reduced. The effects of acarbose may be enhanced.

Adverse Effects:

They include anorexia, nausea, vomiting, epigastric burning and pain, increased gastro-intestinal motility, abdominal cramps, diarrhoea, and pruritus ani. Aminosidine has also been reported to cause hypocholesterolemic and malabsorptive effects. Malabsorption of xylose, sucrose and abnormal fat metabolism have been demonstrated. Aminosidine may also cause steatorrhea by precipitation of bile salts. Other adverse effects reported following oral administration of Aminosidine include rash, headache, vertigo, eosinophilia, exanthema, and unexplained hematuria.


Reporting of suspected adverse reactions:

The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, or clicking below button:

aminosidine price in kenya
Aminosidine price in kenya
aminosidine price in kenya
where to buy Aminosidine (Paromomycin) in Kenya
brands of Aminosidine (Paromomycin) in Kenya

Clinical | Pharmacokinetic data

Pregnancy Category: C
Routes of Administration: By mouth, intramuscular, topical
Bioavailability: Poorly absorbed in the GI tract
Protein Binding: Not Available
Metabolosim: Not available
Onset of Action: N/A
Elimination Half life: Not Available
Excretion: Fecal

Legal Status | Dosage forms & Strengths

Prescription Category:
Prescription only Medicine (POM) , ℞-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:
Tablets | Injectable | Topical gel

Drug Indentifiers:

CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard

Drug Images

References/ Citation:

  • Davidson, Robert N., Margriet den Boer, and Koert Ritmeijer. “Paromomycin.” Transactions of the royal society of tropical medicine and hygiene 103.7 (2009): 653-660.

What was the patient being treated for
%d bloggers like this: